Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riociguat - Bayer

Drug Profile

Riociguat - Bayer

Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Antifibrotics; Antihypertensives; Carbamates; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Raynaud's disease; Systemic scleroderma

Most Recent Events

  • 19 Aug 2019 Bayer completes the phase III PATENT-2 trial in Pulmonary hypertension in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Italy, Japan, South Korea, Mexico, Poland, Portugal, Russia, Singapore, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom and USA (PO, Tablet) (NCT00863681) (EudraCT2008-003610-94)
  • 19 Aug 2019 Bayer completes the phase III CHEST-2 trial in Pulmonary hypertension in USA, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, france, Germany, Israel, Italy, Japan, South Korea, Mexico, Poland, Portugal, Russia, Slovakia, Spain, Switzerland, Taiwan, Turkey, Netherlands and United Kingdom (PO, Tablet) (NCT00910429) (EudraCT2008-003539-19)
  • 12 Jun 2019 Efficacy and adverse events data from the phase II RISE-SSc trial in Systemic scleroderma presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top